LP 659
Alternative Names: AN659; LP-659Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Longboard Pharmaceuticals
- Class Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurological disorders
Most Recent Events
- 02 Dec 2024 Longboard Pharmaceuticals has been acquired by Lundbeck A/S
- 01 Aug 2024 Efficacy and adverse events data from a phase I trial in Neurological disorders were released by Longboard Pharmaceuticals
- 01 Jul 2024 Longboard Pharmaceuticals completes a phase I trial in Neurological disorders (In volunteers) in USA (PO) before July 2024